IngredientsHyaluronic acid (HA) is a naturally occurring non-sulfated glycosaminoglycan (GAG) non-protein compound with distinct physico-chemical properties of repeating ฮฒ-1,4-D-glucuronic acid and ฮฒ-1,3-N-acetylglucosamine units. The term "hyaluronan" was introduced in 1986 to conform to polysaccharide nomenclature. The three terms โ hyaluronic acid, hyaluronan, and hyaluronate โ are used interchangeably in the scientific literature, though technically "hyaluronate" refers to the ionized salt form and "hyaluronan" is the most precise conforming to IUPAC polysaccharide nomenclature. Hyaluronic acid is the only non-sulfated glycosaminoglycan (GAG), essential for maintaining the extracellular matrix's structural and functional integrity.
The molecular weight of hyaluronan is usually in the order of 106 to 107. Due to hydrogen bonding, the chain is rather stiff and the molecule behaves in solution as an extended, randomly kinked coil. Molecules of hyaluronan start to entangle already at concentrations of less than 1 g/L and form a continuous polymer network.
Most cells in the body have the capability to synthesize HA during some point of their cell cycles, implicating its function in several fundamental biological processes. Hyaluronic acid is naturally found in many tissues and fluids, but more abundantly in articular cartilage and synovial fluid. In the human body, HA occurs in the salt hyaluronate form and is found in high concentrations in the skin, umbilical cord, and vitreous humor.
It is found in connective and epithelial tissues in several species, and is moreover secreted in large quantities from the epithelial layers of fish to form protective mucosal slime layers for their skin. HA is also present in the capsules of certain microbial strains (e.g., strains of streptococci). HA is a non-sulfated, naturally occurring non-protein glycosaminoglycan (GAG), produced by synoviocytes, fibroblasts, and chondrocytes.
It is accepted that Hyaluronic Acid (HA) comes from three principal sources: human umbilical cords, rooster combs, and certain bacterial cultures from group A and C hemolytic streptococci. Commercial sources for HA are generally from umbilical cords and rooster combs. However, production methods have shifted markedly over time. Traditionally HA was extracted from rooster combs, and now it is mainly produced via microbial fermentation with excellent viscoelasticity, high moisture retention capacity, and high biocompatibility for wide-range applications in medicine, cosmetics, and nutraceuticals. Traditionally HA was extracted from rooster combs, and now it is mainly produced via streptococcal fermentation.
Currently, commercial hyaluronan is principally produced with biotechnology (microbial fermentation). Microorganism-derived HA is biocompatible with the human body because the HA structure is highly conserved among the different species. Streptococci strains A and C were the first bacteria used for HA production, and nowadays, many commercial products are derived from Streptococcus equi. Hyaluronic acid is also produced via microbial (Streptococcus zooepidemicus, Escherichia coli, Bacillus subtilis, and others) fermentation, and its molecular weight is reported to be controlled by UDP-N-acetylglucosamine concentration. Recently the production of HA via recombinant systems has received increasing interest due to the avoidance of potential toxins.
Due to biocompatibility and a high biodegradation of hyaluronic acid, it finds wide application in bioengineering and biomedicine: from biorevitalizing skin cosmetics and endoprostheses of joint fluid to polymeric scaffolds and wound dressings. HA is commercially available in several distinct forms:
The main properties of aqueous polysaccharide solutions with different molecular weights differ substantially. Moreover, the therapeutic effect of hyaluronic acid-based preparations directly depends on the molecular weight of the biopolymer.
In 1934, Karl Meyer and John Palmer wrote in the Journal of Biological Chemistry about an unusual polysaccharide with an extremely high molecular weight isolated from the vitreous of bovine eyes. The substance contained a uronic acid and an amino sugar, but no sulfoesters. Meyer's discovery is frequently referred to as hyaluron in vivo and Hyaluronic Acid (HA) ex vivo. The precise chemical structure was determined 20 years later and classified as part of biologically active molecules known as glycosaminoglycans (GAGs).
In the short period between 1948 and 1951, several chemists initiated research to elucidate the structure of hyaluronic acid. During the second half of the twentieth century, hyaluronic acid (HA) was discovered in different tissues and liquids of vertebrate animals as well as humans. It was also found to have clinical applications, mostly for eye surgery, treatment of joint diseases and aesthetic medicine.
HA has no traditional ethnobotanical history of use, as it is not derived from a botanical source and was not isolated until 1934. Its history is therefore entirely scientific and medical. Medical studies of HA include its role in fertilization, embryogenesis, development of the immune response, the healing of wounds, oncological and infectious diseases, processes of ageing and the problems of aesthetic medicine.
In 1980, one of the first hyaluronic acid products was introduced. Named Healon, it was a product used in cataract surgery and is still manufactured to date. HA has been used for more than four decades in the treatment of OA in dogs, horses and humans. Clinical trials have demonstrated the efficacy of sodium hyaluronate eye drops as a viable treatment option for dry eye syndrome. With the earliest clinical trials dating back to 1986, hyaluronic acid eye drops can be considered an "old hero" in the fight against dry eye disease.
Hyaluronic acid is composed of disaccharide repeats of D-glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc) joined alternately by ฮฒ-1,3 and ฮฒ-1,4 glycosidic bonds. The molecular weights of HA from different sources are highly variable, ranging from 104 to 107 Da. Hyaluronic acid has strong hydrophilic properties and can regulate the viscoelasticity of biological fluids by forming non-covalent bonds with water molecules, playing an important role in cell migration and proliferation.
Hyaluronan is synthesized in the cell membrane by adding monosaccharides to the reducing end of the chain. The precursors are UDP-glucuronic acid and UDP-N-acetylglucosamine. The polysaccharide grows out from the cell surface and fibroblasts surround themselves with a coat of hyaluronan. The rate of biosynthesis is regulated by various factors, such as growth factors, hormones, and inflammatory mediators. The responsible enzyme, hyaluronan synthase, is a phosphoprotein and the regulation of the synthetic rate is apparently via phosphorylation.
In cells, HA synthesis is connected with HA-synthesizing (HAS) enzymes โ HAS1, HAS2, HAS3 โ anchored in the membrane. Each enzyme produces a specific molecular weight and synthesizes HA at the inner face, with possible translocation of the polysaccharide into the extracellular space.
Metabolic pathways for biosynthesis and degradation tightly control the turnover rate, concentration, and molecular size of hyaluronan in tissues. HA can be catabolized by three hyaluronidases (HYAL): (1) HYAL1 is associated with lysosomes and degrades HA into tetrasaccharides; (2) HYAL2 degrades HA of higher molecular weight into products of 20 kDa; (3) details of HYAL3 have yet to be elucidated. HYAL1, HYAL2, CEMIP (cell migration-inducing hyaluronidase), and TMEM2 (transmembrane protein 2) are active in both the dermis and the epidermis.
The hyaluronan is at least partly carried by lymph flow from the tissues. Part of the material is taken up and degraded in the lymph nodes. Another part is carried to the general circulation and taken up in endothelial cells in the liver sinusoids.
HA was initially considered to be only an inert component of connective tissues, but is now known as a "dynamic" molecule with a constant turnover in many tissues through rapid metabolism that involves HA molecules of various sizes: high molecular weight HA (HMW HA), low molecular weight HA, and oligosaccharides.
Beyond its roles in energy storage and structural support, HA acts as a biologically active signaling molecule, influencing processes like cell adhesion, migration, angiogenesis, and inflammation. The biological function of HA is closely related to its molecular weight. Different molecular weights of HA have different distributions, metabolic pathways, and interactions with cell surface receptors in the body, and thus exhibit different biological activities.
HA is known to have an important role in wound healing and scar formation. Products of HA degradation (low molecular weight HA) were found to contribute to the scar formation process. Moreover, scar formation was minimized when high molecular weight HA was found in wound fluid during fetal wound healing. These results suggested that the molecular weight of HA plays a significant role in wound healing and scar formation.
Fragments generated by the hyaluronidase-catalyzed digestion of HMW HA function as pro-inflammatory damage-associated molecular patterns and stimulate inflammation via TLR2 and/or TLR4 in immune cells.
The glycosaminoglycan hyaluronan (HA), a major component of extracellular matrices, and cell surface receptors of HA have been proposed to have pivotal roles in cell proliferation, migration, and invasion, which are necessary for inflammation and cancer progression. CD44 and receptor for HA-mediated motility (RHAMM) are the two main HA-receptors whose biological functions in human and murine inflammations and tumor cells have been comprehensively investigated.
HA exerts its effects at the cellular level primarily through interactions with cell surface receptors such as CD44, RHAMM, and Toll-like receptors (TLR2/4). CD44 is a principal HA receptor expressed on keratinocytes and fibroblasts. Upon HA binding, CD44 activates downstream signaling cascades, including the MAPK/ERK and PI3K/Akt pathways.
In addition to CD44 and RHAMM, two other receptors have been identified for HA binding: (1) lymphatic vessel endothelial hyaluronan receptor (LYVE-1), and (2) hyaluronic acid receptor for endocytosis (HARE), also known as Stabilin-2.
Cells sense biophysical properties of extracellular HA through surface receptors such as CD44 and RHAMM. These biophysical properties influence cell adhesion, migration, and proliferation through cytoskeletal interactions, transcription, and receptor crosstalk.
HA is a non-sulfated, naturally occurring non-protein glycosaminoglycan (GAG), produced by synoviocytes, fibroblasts, and chondrocytes. HA has an important role in the biomechanics of normal synovial fluid, where it is partially responsible for lubrication and viscoelasticity. The concentration of HA and its molecular weight decline as osteoarthritis (OA) progresses with aging.
The decline in HA levels with age is one of the key factors contributing to the visible signs of aging, such as wrinkles, loss of volume, and reduced skin elasticity. As HA content decreases, the skin becomes drier and more prone to damage, with a reduced capacity for regeneration. At the cellular level, HA supports the optimal function of keratinocytes by forming a protective barrier that reduces transepidermal water loss. By enhancing ECM hydration, it contributes to skin elasticity, smoothness, and structural resilience.
HA deposition and degradation play essential roles in regulating inflammatory responses. Expression of the genes related to HA biosynthesis and degradation are upregulated in response to inflammatory cytokines, resulting in increased HA turnover during inflammatory responses. High-molecular-weight HA (HMW-HA) is considered anti-allergic, whereas low-molecular-weight HA (LMW-HA) is considered pro-allergic.
A total of 7 randomized controlled trials (RCTs) on the use of oral HA as a supplement have been identified and subjected to meta-analysis, comparing standardized mean differences between the treatment (HA) and control (placebo) groups. The meta-analysis revealed statistically significant improvements in skin hydration, elasticity, and wrinkle depth following oral HA supplementation. Although the effects of oral HA on skin firmness, wrinkle volume, and transepidermal water loss were not statistically significant, a general trend of improvement was observed in these parameters.
The findings align with existing literature, underscoring the potential of oral HA supplementation as a valuable component in anti-aging and skincare regimens. However, the study's limited sample size and heterogeneity among included studies call for larger, more robust trials to confirm these findings.
One notable double-blind RCT enrolled 129 female participants across both young and elderly groups. The results indicated that oral intake of HMW-HA (300 kDa) at the levels of 100 and 200 mg/day can promote skin hydration after 2โ8 weeks, and the effect is statistically significant for both young and elderly groups. Oral administration of HA significantly promoted skin hydration after 2โ8 weeks among both young and elderly groups. Skin tone improvement was observed after 4โ8 weeks, while an increase in epidermal thickness was noted after 12 weeks.
Another clinical study evaluated an oral HA preparation in 20 female subjects aged 45โ60 years. An oral HA preparation diluted in a cascade-fermented organic whole food concentrate supplemented with biotin, vitamin C, copper, and zinc was evaluated. Twenty female subjects with healthy skin in the age group of 45 to 60 years took the product once daily for 40 days. Different skin parameters were objectively assessed before the first intake, after 20 and after 40 days. Intake of the HA solution led to a significant increase in skin elasticity, skin hydration, and to a significant decrease in skin roughness and wrinkle depths. This was a small, industry-associated study without placebo control, limiting interpretation.
A 12-week RCT including 60 healthy women aged 35โ65 years tested HAm (Dermialยฎ) at 60 mg daily. Conclusions indicated that daily supplementation with HAm effectively improves multiple aspects of skin health and appearance, suggesting its potential as a safe and beneficial antiaging ingredient. This study was industry-funded, which the authors disclosed.
By pooling standardized data, researchers found that daily HA supplementation delivers statistically significant improvements in skin hydration and elasticity, alongside a measurable decrease in wrinkle depth. A meta-analysis of seven RCTs offers dermatologists a fresh look at oral hyaluronic acid's role in skin health. Although trends toward enhanced firmness and reduced transepidermal water loss did not meet statistical significance, the consistent direction of results suggests true biological promise.
Evidence strength: Moderate-to-preliminary. Multiple small RCTs and a meta-analysis support short-term improvements in skin hydration, elasticity, and wrinkle depth with oral HA. Limitations include small sample sizes, heterogeneity in HA molecular weight and dose, variable study duration, and industry funding in several trials.
Thirty-eight randomized control trials (RCTs) investigating the efficacy and safety of intra-articular injection of HA have been included in one PRISMA-compliant systematic review. A total of 5,025 patients were included in these studies. The mean age of the patients was 60.28 years and the osteoarthritis grade of the knee joint was 1 to 3.
Intra-articular hyaluronic acid (IAHA) showed moderate efficacy in pain relief and functional improvement, especially in early-to-moderate OA. The analysis showed that both HA and PRP significantly improve functionality and reduce pain in knee OA patients.
Comparing short-term outcomes of HA injections with oral NSAIDs for treatment of knee OA, HA injections provided statistically significant but not clinically important improvements in knee pain and function, along with a lower overall risk of adverse events.
Systematic reviews of treatment efficacy and adverse events of hyaluronic acid injections report conflicting evidence about the balance of benefits and harms. Controversies exist regarding its safety and efficacy, the number of injections and courses, type of preparation, duration of its effects, and combining it with other drugs or molecules.
The concentration of HA and its molecular weight decline as osteoarthritis progresses with aging. For that reason, HA has been used for more than four decades in the treatment of OA in dogs, horses and humans. HA produces anti-arthritic effects via multiple mechanisms involving receptors, enzymes and other metabolic pathways.
Evidence strength: Moderate and contested. Multiple systematic reviews confirm statistical benefits in pain and function for knee OA, particularly in early-to-moderate disease. However, several guideline bodies have debated clinical significance, and evidence is conflicting across meta-analyses regarding magnitude of benefit and comparison with placebo saline injections.
As a component of the tear film, HA increases the viscosity of the tear film and hydrates and lubricates the ocular surface. HA possesses intrinsic water retention properties, viscoelasticity, and favors the healing of corneal and conjunctival epithelium.
Topical use of HA provides both objective and subjective symptomatic relief in patients with dry eye disease. Clinical trials have demonstrated the efficacy of sodium hyaluronate eye drops as a viable treatment option for dry eye syndrome. With the earliest clinical trials dating back to 1986, hyaluronic acid eye drops can be considered an "old hero" in the fight against dry eye disease.
Ophthalmic preparations containing hyaluronic acid have been reported to be used successfully in various pathological disorders of the physiology and morphology of the eye. HA reduces the symptoms of dry eye disease by stabilising the tear film, reducing friction during blinking, and it prevents harmful substances from binding to the eye.
Evidence strength: Well-established. HA-based ophthalmic preparations have a clinical track record of nearly four decades, supported by multiple clinical trials, and sodium hyaluronate is a standard ingredient in artificial tear formulations. The evidence base for symptomatic relief and surface protection in dry eye disease is robust relative to other HA indications.
Genetic engineering and pharmacological approaches have demonstrated close associations between hyaluronan metabolism and functions in many physiological and pathological events, including morphogenesis, wound healing, and inflammation.
The early appearance of higher-MW HA and the later appearance of lower-MW HA at the wound site, as HA is degraded, provides a mechanism to regulate and integrate the timing of the cellular activities needed to initiate and sustain the inflammatory response and the wound healing process.
Natural biodegradable polymers, which include collagen, cellulose, chitosan, and hyaluronic acid (HA), have shown high biocompatibility and efficacy in promoting wound healing. Hydrogels based on hyaluronic acid as the main active ingredient are also widely used in nerve repair, wound healing, and vascular regeneration.
Evidence strength: Moderate for clinical wound healing; the mechanistic basis is well-described in the literature, and HA-based wound dressings are used in clinical practice. Randomized trial evidence specifically isolating topical HA versus standard care is less extensive than for joint or ophthalmic indications.
In recent years, the clinical application of HA dermal fillers has expanded significantly, prompting the development of expert consensus recommendations to ensure safe and effective use. HA is a natural component of many soft tissues and is identical across species, minimising immunogenicity.
A meta-analysis reports comprehensive evidence on the effectiveness and safety of hyaluronic acid (HA) fillers for midface augmentation. The combined responder rate strongly favors HA over placebo (RR = 53.62, 95% CI 7.15โ402.01, p < 0.0001), with no heterogeneity, indicating a significant clinical benefit compared to no treatment.
Evidence strength: Strong for short-term aesthetic outcomes. HA dermal fillers are among the most extensively used and studied aesthetic interventions, with robust RCT evidence supporting efficacy in facial volumization and wrinkle reduction. Long-term outcome data and head-to-head comparisons across formulations are more limited.
The earliest medical application of HA was as a viscoelastic agent in ophthalmic surgery. In 1980, one of the first hyaluronic acid products โ Healon โ was introduced, used in cataract surgery, and is still manufactured to date. In this setting, HA functions not as a supplement but as a medical device-class viscoelastic, protecting ocular tissues during intraocular surgery. This application is well-established and FDA-approved in the United States.
Preliminary evidence has shown that intravesical HA, administered alone or in combination with chondroitin sulfate or alpha blockers, could be able to reduce the recurrence of urinary tract infections such as bacterial cystitis, to alleviate the symptoms of these diseases and to protect the mucosa of the urinary bladder. However, further clinical studies are necessary to establish this indication conclusively.
Evidence strength: Preliminary. The intravesical indication is supported by limited clinical evidence and requires larger, well-designed RCTs.
The following dosages are those reported specifically in published clinical studies or systematic reviews; they are not recommendations.
When taken orally, the supplement was well tolerated; no side effects were noted throughout one study. The evidence consistently demonstrates excellent tolerability: adverse events are rare and mild across clinical trials examining oral HA supplementation. No serious adverse events have been reported in systematic reviews of oral HA use. When adverse effects do occur, they are typically gastrointestinal symptoms (mild and self-limiting).
Oral HA is degraded by intestinal bacteria in the cecum into oligosaccharides, not by gastric or small intestinal juices.
Adverse effects of intra-articular injections of hyaluronic acid are usually mild and self-limiting. Local injection site reactions or irritation are the most common side effects. Up to 2% of patients can experience a post-injection flare with more pain, swelling, redness, and warmth, which is usually self-limited and can resolve with icing, rest, and anti-inflammatory medication.
The most common adverse effects associated with hyaluronic acid filler are pain, bruising, redness, itching, and swelling. These side effects are self-limited and typically last no more than seven days.
Hyaluronic acid-based dermal fillers have a low overall incidence of long-term side effects; occasional adverse outcomes, ranging from chronic lymphoplasmacytic inflammatory reactions to classic foreign body-type granulomatous reactions, have been documented.
Despite their favorable safety profile, HA fillers can still lead to adverse events, ranging from transient swelling and bruising to rare but serious complications like vascular occlusion and skin necrosis.
Adverse effects, including granuloma formation, delayed hypersensitivity reactions, and vascular complications, although rare, have been reported in post-marketing surveillance and clinical studies. These concerns highlight the need for standardized formulations, long-term safety data, and individualized treatment planning.
Thrombin-induced formation of fibrin clots is affected by HA, which decreases the lag time before clotting and increases the rate of clot formation. It is noteworthy that an increase in circulating HA levels could adversely affect hemostasis and increase the risk of thrombosis or bleeding. This is a theoretical mechanistic concern; it has been documented in in-vitro and biochemical contexts but clinical significance for supplemental doses has not been established.
As streptococci genera include several human pathogens, an accurate and expensive purification of the produced HA is necessary when using fermentation-derived HA. Individuals with known hypersensitivity to Streptococcal products should be aware that some commercial HA preparations are derived from streptococcal fermentation. Additionally, products derived from rooster comb may be inappropriate for individuals with poultry allergies, though the HA molecule itself is identical across species.
Health conditions that Hyaluronic acid may help support.
Hyaluronic acid (HA) is a natural component of synovial fluid and articular cartilage, used as intra-articular injection (viscosupplementation) and increasingly as an oral supplement for osteoarthritis. Intra-articular HA has extensive RCT and meta-analysis support for knee OA pain reduction. Oral HA has emerging pilot evidence for joint pain.
Intervertebral disc (IVD) degeneration is a leading cause of low back pain, and HA is a natural component of the disc extracellular matrix. Intradiscal HA injection has been explored in early-phase human trials and preclinical models. High-molecular-weight HA has shown anti-inflammatory and analgesic properties in IVD models, though robust randomized controlled trials in humans remain limited. Oral HA for low back pain has only one identified clinical study to date.
Hyaluronic acid is a key glycosaminoglycan component of the bladder's protective mucosal layer, disrupted in interstitial cystitis (IC/BPS). Intravesical hyaluronic acid instillation is an established clinical treatment for IC. Oral supplementation alongside other GAG components (glucosamine, chondroitin, quercetin) showed significant IC symptom reduction in a 252-patient study.
Hyaluronic acid (HA) is a key component of the extracellular matrix and wound-healing cascade, widely used in burn and wound dressings. It promotes moist wound healing, cell migration, and tissue regeneration. HA-based dressings have clinical evidence for efficacy in partial-thickness burns and are included in biopolymeric wound dressing formulations supported by multiple clinical trials.
Hyaluronic acid (HA) has been evaluated in multiple clinical studies and a systematic review for recurrent aphthous stomatitis. A 2021 systematic review in Clinical Oral Investigations confirmed HA's efficacy in managing RAS signs and symptoms via its barrier-forming, anti-inflammatory, and wound-healing properties. A retrospective clinical study (BMC Oral Health 2019; PMC6636158) found both HA mouth rinse and HA gel effective for minor RAS with improved healing onset.
Hyaluronic acid (HA) is a non-sulfated glycosaminoglycan and natural component of both articular cartilage and synovial fluid, where it maintains viscoelasticity, lubrication, and shock absorption. It is recognized alongside glucosamine sulfate, chondroitin sulfate, and collagen hydrolysate as an established chondroprotective nutraceutical. Oral HA supplementation has demonstrated joint pain benefits in clinical studies, and a 2022 retrospective RCT combining native type II collagen with HA demonstrated improvements in WOMAC and cartilage degeneration biomarkers.
Hyaluronic acid (HA) is a major component of synovial fluid providing joint lubrication and cushioning. Intra-articular HA injections are established for chronic osteoarthritis knee pain. Oral HA supplementation has emerging evidence for reducing OA joint pain and stiffness, with some RCTs showing benefit.
Hyaluronic acid is a naturally occurring glycosaminoglycan that forms the backbone of proteoglycans and maintains hydration and elasticity in connective tissues, including cartilage, tendons, and skin. A clinical trial (n=40) found that oral hyaluronic acid combined with Boswellia extract significantly decreased pain and improved knee function in mild-to-moderate OA over 6 months. It is a well-established component of articular connective tissue.
Hyaluronic acid is used topically and as an injectable filler in the periorbital area to plump thinned skin, reducing the structural shadowing that contributes to dark circle appearance. A 2019 clinical trial reported a 26% improvement in under-eye dark circles and significant reduction in fine lines with 1% hyaluronic acid gel. As an injected filler, it is used for three-dimensional reshaping of the periorbital complex.
Oral hyaluronic acid supplementation combined with topical HA more efficiently improves corneal epithelial wound healing and DED symptoms than topical HA alone, per a pilot study. Topical HA combined with CoQ10 and vitamin E shows clinical improvements in DED. Hyaluronic acid is a humectant that attracts water and promotes ocular surface hydration and repair.
Hyaluronic acid (HA) is a key endogenous skin humectant capable of binding up to 1000x its weight in water. Multiple randomized double-blind placebo-controlled trials confirm that both topical and oral HA significantly improve skin hydration and reduce dry skin symptoms. A 12-week RCT (n=40) found significantly higher stratum corneum water content in the HA group vs. placebo.
Hyaluronic acid (HA) is a key glycosaminoglycan in synovial fluid that maintains joint viscosity, cushioning, and lubrication. Intra-articular HA injection has long-established clinical use; oral HA has been evaluated in a double-blind placebo-controlled 12-month study and showed alleviation of knee OA symptoms. HA improves synovial fluid elasticity, decreases pain-producing neuropeptides, and exerts anti-inflammatory effects including IL-1 suppression.
Hyaluronic acid, the primary glycosaminoglycan of the vitreous humor, was included in the 2025 pilot RCT combination supplement (n=40 eyes) for post-Nd:YAG floaters that showed significant improvements in floater perception and contrast sensitivity. Its depolymerization with ageing directly underlies floater formation, and HA is used as a vitreous substitute in ophthalmic surgery.
Multiple randomized controlled trials support the adjunctive use of locally applied hyaluronic acid gel in non-surgical periodontal therapy. HA reduces bleeding on probing and improves clinical attachment levels when added to standard scaling and root planing. Evidence covers both generally healthy patients and those with type 2 diabetes.
Hyaluronic acid (HA) is a glycosaminoglycan that declines with age in skin and joints, contributing to loss of hydration, elasticity, and joint lubrication. Randomized clinical trials confirm oral HA supplementation (120โ240 mg/day) improves skin hydration, elasticity, and wrinkle appearance in middle-aged adults. Topical and intra-articular HA also have established evidence bases.
Hyaluronic acid (hyaluronate) is a natural GAG with the longest evidence base in IC, primarily via intravesical instillation (standard therapy in Europe and Canada, with up to 85% improvement rates). Oral hyaluronate (40 mg/day) has also been trialed as part of multi-agent CystoProtek in 252 refractory IC patients with significant symptom improvement.
A 2024 split-body randomized clinical trial published in the Journal of Cosmetic Dermatology found that injected non-cross-linked hyaluronic acid compound significantly improved skin roughness and promoted hair shaft growth in KP patients, with improvements maintained up to 24 weeks. This represents the first clinical trial demonstrating HA's utility specifically in KP.
Vaginal HA formulations have demonstrated clinical efficacy in reducing genitourinary syndrome of menopause (GSM) symptoms โ including dryness, burning, and dyspareunia โ in multiple RCTs. A 2026 systematic review and meta-analysis confirmed HA as a safe, effective non-hormonal option with moderate-quality evidence. HA's strong water-binding properties restore mucosal hydration and viscoelasticity compromised by postmenopausal hypoestrogenism.
Hyaluronic acid (HA) has immunomodulatory and regenerative functions showing emerging evidence for post-surgical tissue repair and symptom relief. A 2025 narrative orthopaedic review identifies HA as an emerging nutraceutical for post-surgical connective tissue regeneration. A 2023 double-blind RCT in Mohs surgery used a hyaluronan-containing supplement and assessed wound healing outcomes.
Intra-articular HA injection has been studied in rheumatoid arthritis (RA) patients, particularly for joints with concurrent osteoarthritis. Serum HA levels are elevated in active RA and correlate with disease activity markers. Clinical trials are limited in number and size; most evidence comes from RA patients with coexistent knee osteoarthritis rather than pure inflammatory RA.
Hyaluronic acid is a key ECM glycosaminoglycan that modulates wound healing and scar formation. It promotes cell activation, migration, and neovascularization during the scar remodeling phase and has been studied in clinical wound healing formulations, showing improved scar organization.
Hyaluronic acid (HA) is the key glycosaminoglycan maintaining skin hydration and dermal volume, declining markedly with aging. Multiple RCTs of oral HA supplementation (80โ200 mg/day, 40โ90 days) demonstrate significant improvements in wrinkle depth, hydration, and elasticity. A 2025 meta-analysis of 7 RCTs confirmed efficacy for wrinkle reduction with oral HA supplementation.
Hyaluronic acid (HA) is a key glycosaminoglycan of the dermal ECM that retains water and supports skin elasticity by stimulating fibroblast production of collagen, elastin, and ECM proteins. A 2025 RCT of oral sodium hyaluronate in 150 adults over 3 months documented improvements in skin elasticity, collagen density, hydration, and wrinkle depth. HA levels in skin decline markedly with age, driving loss of elasticity.
Hyaluronic acid (HA) injections have been evaluated in RCTs for lateral ankle sprains, showing significant improvements in pain and function. A systematic review including ankle sprains demonstrates consistent benefit for soft tissue indications.
Hyaluronic acid (HA) intra-articular injections are one of the most studied interventions for TMJ disorders. A 2010 systematic review of 19 studies reported decreased pain across all protocols. A 2016 RCT found HA injections superior to splint therapy for pain, maximum mouth opening, and quality of life at 6 months. A 2025 systematic review confirmed HA improves TMJ biomechanics.
Hyaluronic acid is a glycosaminoglycan naturally present in the bladder glycosaminoglycan (GAG) layer, which forms a protective barrier against bacterial adhesion. Intravesical hyaluronic acid instillation is used clinically to restore GAG layer integrity and prevent recurrent UTIs. Multiple clinical studies and a 2023 PMC review confirm its role as a novel key ingredient in urinary tract health.
Clinical studies show that vaginally applied HA reduces elevated vaginal pH and improves vaginal maturation index, supporting a more favorable mucosal environment for Lactobacillus-dominated flora. These effects have been demonstrated in postmenopausal women, postpartum women, and endometrial cancer survivors. HA's water-binding properties restore epithelial health, indirectly supporting normal vaginal ecology.
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan critical to wound healing, modulating inflammation, cell migration, and tissue regeneration. HA-based wound dressings are widely used clinically, and multiple studies demonstrate they accelerate healing in chronic wounds, burns, and surgical sites.
Body systems that Hyaluronic acid may help support.
Go back